11 completed, 1 recruiting, 1 unknown. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bicalutamide Therapy in Young Women With NAFLD and PCOS Bicalutamide 50 mg, Placebo - NAFLD, PCOS | Phase 1 | Recruiting | University of California, San Francisco | 50 | 2024-02-14 | 2026-05-29 |
| Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis | Phase 1 / Phase 2 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 30 | 2023-07-05 | 2026-04-15 |
| Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD GH509, Placebo - NASH, NAFLD | Phase 1 / Phase 2 | Unknown | 1Globe Biomedical Co., Ltd. | 180 | 2023-02-28 | 2023-03-28 |
| The Effects of Glucagon on Hepatic Metabolism Glucagon response study - Obesity, Type2diabetes | Phase 1 / Phase 2 | Completed | Adrian Vella | 21 | 2022-10-20 | 2026-11-04 |
| Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease AZD7503 Intervention - Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 1 | Completed | AstraZeneca | 19 | 2022-08-12 | 2025-07-20 |
| DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD. ASC41, Itraconazole, Phenytoin - Healthy, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 24 | 2021-03-16 | 2024-09-27 |
| A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD DD01, Placebo - Overweight and Obesity, Type2 Diabetes | Phase 1 | Completed | Neuraly, Inc. | 255 | 2021-02-24 | 2024-04-29 |
| Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers ASC41 tablet - Healthy, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 12 | 2020-12-27 | 2024-09-27 |
| Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects ASC 41, ASC 41 Placebo - Overweight and Obesity, NAFLD | Phase 1 | Completed | Gannex Pharma Co., Ltd. | 20 | 2020-12-22 | 2024-09-27 |
| Study of NGM395 in Adult Participants NGM395, Placebo - Obesity, NAFLD | Phase 1 | Completed | NGM Biopharmaceuticals, Inc | 38 | 2020-02-13 | 2021-07-21 |
| A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD HM15211, Placebo of HM15211 - NAFLD | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 66 | 2018-11-01 | 2025-01-27 |
| An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function BMS-986036 - NAFLD, Nonalcoholic Fatty Liver Disease | Phase 1 | Completed | Bristol-Myers Squibb | 40 | 2018-09-11 | 2019-10-08 |
| Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) RYI-018, Placebo - NAFLD | Phase 1 | Completed | Bird Rock Bio, Inc. | 84 | 2017-08-28 | 2019-03-14 |
Non-alcoholic Fatty Liver Disease (13) · Obesity (4) · Hyperlipidemias (2) · Overweight (2) · Fatty Liver (1) · Insulin Resistance (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Digestive System Diseases (13) · Fatty Liver (12) · Liver Diseases (12) · Nutritional and Metabolic Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Body Weight (4) · Nutrition Disorders (4) · Overnutrition (4) · Signs and Symptoms (4) · Metabolic Diseases (3) · Dyslipidemias (2) · Lipid Metabolism Disorders (2) · Overweight (2) · Fibrosis (1) · Glucose Metabolism Disorders (1)
Dasatinib (1) · Glucagon (1) · Itraconazole (1) · Pegbelfermin (1) · Phenytoin (1) · Quercetin (1) · bicalutamide (1)
Gannex Pharma Co., Ltd. (3) · 1Globe Biomedical Co., Ltd. (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Adrian Vella (1) · AstraZeneca (1) · Bird Rock Bio, Inc. (1) · Bristol-Myers Squibb (1) · Hanmi Pharmaceutical Company Limited (1) · NGM Biopharmaceuticals, Inc (1) · Neuraly, Inc. (1) · University of California, San Francisco (1)
United States (7) · China (3) · Australia (2) · Canada (1) · Czechia (1) · Hungary (1) · Netherlands (1) · Puerto Rico (1)
Adrian Vella (1) · Max Nieuwdorp, MD, PhD (1) · Monika A Sarkar, MD, MAS (1)
2018 (1), R01DK116231 (1), R01DK134633 (1)